Traynor Capital Management, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Traynor Capital Management, Inc.
- $1.47 Billion
- Q4 2024
A detailed history of Traynor Capital Management, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Traynor Capital Management, Inc. holds 9,350 shares of ALNY stock, worth $2.49 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
9,350
Previous 7,249
28.98%
Holding current value
$2.49 Million
Previous $1.99 Million
10.33%
% of portfolio
0.15%
Previous 0.12%
Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
645Shares Held
109MCall Options Held
1.28MPut Options Held
1.22M-
Capital World Investors Los Angeles, CA16.5MShares$4.4 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.37 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.54 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.4 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.32 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $32.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...